Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

Cardiotonic steroids induce vascular fibrosis via pressure-independent mechanism in NaCl-loaded diabetic rats.

Fedorova OV, Fadeev AV, Grigorova YN, Marshall CA, Zernetkina V, Kolodkin NI, Agalakova NI, Konradi AO, Lakatta EG, Bagrov AY.

J Cardiovasc Pharmacol. 2019 Aug 1. doi: 10.1097/FJC.0000000000000730. [Epub ahead of print]

PMID:
31415452
2.

Acute salt loading and cardiotonic steroids in resistant hypertension.

Emelyanov IV, Konradi AO, Lakatta EG, Fedorova OV, Bagrov AY.

Curr Top Membr. 2019;83:1-13. doi: 10.1016/bs.ctm.2019.01.005. Epub 2019 Feb 18.

PMID:
31196601
3.

Large artery stiffness is associated with marinobufagenin in young adults: the African-PREDICT study.

Strauss M, Smith W, Wei W, Bagrov AY, Fedorova OV, Schutte AE.

J Hypertens. 2018 Dec;36(12):2333-2339. doi: 10.1097/HJH.0000000000001866.

4.

Dietary Sodium Restriction Reduces Arterial Stiffness, Vascular TGF-β-Dependent Fibrosis and Marinobufagenin in Young Normotensive Rats.

Grigorova YN, Wei W, Petrashevskaya N, Zernetkina V, Juhasz O, Fenner R, Gilbert C, Lakatta EG, Shapiro JI, Bagrov AY, Fedorova OV.

Int J Mol Sci. 2018 Oct 15;19(10). pii: E3168. doi: 10.3390/ijms19103168.

5.

Telocinobufagin, a Novel Cardiotonic Steroid, Promotes Renal Fibrosis via Na⁺/K⁺-ATPase Profibrotic Signaling Pathways.

Kennedy DJ, Khalaf FK, Sheehy B, Weber ME, Agatisa-Boyle B, Conic J, Hauser K, Medert CM, Westfall K, Bucur P, Fedorova OV, Bagrov AY, Tang WHW.

Int J Mol Sci. 2018 Aug 29;19(9). pii: E2566. doi: 10.3390/ijms19092566.

6.

Antibody to Marinobufagenin Reverses Placenta-Induced Fibrosis of Umbilical Arteries in Preeclampsia.

Fedorova OV, Ishkaraeva VV, Grigorova YN, Reznik VA, Kolodkin NI, Zazerskaya IE, Zernetkina V, Agalakova NI, Tapilskaya NI, Adair CD, Lakatta EG, Bagrov AY.

Int J Mol Sci. 2018 Aug 13;19(8). pii: E2377. doi: 10.3390/ijms19082377.

7.

Marinobufagenin in Urine: A Potential Marker of Predisposition to Ethanol and a Target for Spironolactone.

Kashkin VA, Shekunova EV, Egorov AY, Bagrov AY.

Curr Hypertens Rev. 2018;14(1):35-38. doi: 10.2174/1573402114666180212115518.

PMID:
29437012
8.

Comparison of Digitalis Sensitivities of Na+/K+-ATPases from Human and Pig Kidneys.

Gable ME, Ellis L, Fedorova OV, Bagrov AY, Askari A.

ACS Omega. 2017 Jul 31;2(7):3610-3615. doi: 10.1021/acsomega.7b00591. Epub 2017 Jul 13.

9.

Selective ligands for Na+/K+-ATPase α isoforms differentially and cooperatively regulate excitability of pyramidal neurons in distinct brain regions.

Chakraborty D, Fedorova OV, Bagrov AY, Kaphzan H.

Neuropharmacology. 2017 May 1;117:338-351. doi: 10.1016/j.neuropharm.2017.02.016. Epub 2017 Feb 20.

PMID:
28232062
10.

The Pressure of Aging.

AlGhatrif M, Wang M, Fedorova OV, Bagrov AY, Lakatta EG.

Med Clin North Am. 2017 Jan;101(1):81-101. doi: 10.1016/j.mcna.2016.08.006. Review.

11.

Rapamycin Attenuates Cardiac Fibrosis in Experimental Uremic Cardiomyopathy by Reducing Marinobufagenin Levels and Inhibiting Downstream Pro-Fibrotic Signaling.

Haller ST, Yan Y, Drummond CA, Xie J, Tian J, Kennedy DJ, Shilova VY, Xie Z, Liu J, Cooper CJ, Malhotra D, Shapiro JI, Fedorova OV, Bagrov AY.

J Am Heart Assoc. 2016 Sep 30;5(10). pii: e004106.

12.

Synthesis of an Endogenous Steroidal Na Pump Inhibitor Marinobufagenin, Implicated in Human Cardiovascular Diseases, Is Initiated by CYP27A1 via Bile Acid Pathway.

Fedorova OV, Zernetkina VI, Shilova VY, Grigorova YN, Juhasz O, Wei W, Marshall CA, Lakatta EG, Bagrov AY.

Circ Cardiovasc Genet. 2015 Oct;8(5):736-45. doi: 10.1161/CIRCGENETICS.115.001217. Epub 2015 Sep 15.

13.

Aortic Fibrosis, Induced by High Salt Intake in the Absence of Hypertensive Response, is Reduced by a Monoclonal Antibody to Marinobufagenin.

Grigorova YN, Juhasz O, Zernetkina V, Fishbein KW, Lakatta EG, Fedorova OV, Bagrov AY.

Am J Hypertens. 2016 May;29(5):641-6. doi: 10.1093/ajh/hpv155. Epub 2015 Sep 7.

14.

Elevated Plasma Marinobufagenin, An Endogenous Cardiotonic Steroid, Is Associated With Right Ventricular Dysfunction and Nitrative Stress in Heart Failure.

Kennedy DJ, Shrestha K, Sheehey B, Li XS, Guggilam A, Wu Y, Finucan M, Gabi A, Medert CM, Westfall K, Borowski A, Fedorova O, Bagrov AY, Tang WH.

Circ Heart Fail. 2015 Nov;8(6):1068-76. doi: 10.1161/CIRCHEARTFAILURE.114.001976. Epub 2015 Aug 14.

15.

The effect of marinobufagenin on the growth and proliferation of cells in the organotypic culture.

Penniyaynen VA, Kipenko AV, Lopatina EV, Bagrov AY, Krylov BV.

Dokl Biol Sci. 2015;462:164-6. doi: 10.1134/S0012496615030096. Epub 2015 Jul 12.

PMID:
26164341
16.

Marinobufagenin-induced vascular fibrosis is a likely target for mineralocorticoid antagonists.

Fedorova OV, Emelianov IV, Bagrov KA, Grigorova YN, Wei W, Juhasz O, Frolova EV, Marshall CA, Lakatta EG, Konradi AO, Bagrov AY.

J Hypertens. 2015 Aug;33(8):1602-10. doi: 10.1097/HJH.0000000000000591.

17.

Plasma level of the endogenous sodium pump ligand marinobufagenin is related to the salt-sensitivity in men.

Fedorova OV, Lakatta EG, Bagrov AY, Melander O.

J Hypertens. 2015 Mar;33(3):534-41; discussion 541. doi: 10.1097/HJH.0000000000000437.

18.

Modulating effect of the cardiotonic steroid marinobufagenin on slow sodium channels.

Shelykh TN, Plakhova VB, Podzorova SA, Bagrov AY, Krylov BV.

Dokl Biol Sci. 2014 Sep;458:278-80. doi: 10.1134/S0012496614050111. Epub 2014 Nov 5. No abstract available.

PMID:
25371252
19.

Dietary sodium restriction and association with urinary marinobufagenin, blood pressure, and aortic stiffness.

Jablonski KL, Fedorova OV, Racine ML, Geolfos CJ, Gates PE, Chonchol M, Fleenor BS, Lakatta EG, Bagrov AY, Seals DR.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1952-9. doi: 10.2215/CJN.00900113. Epub 2013 Aug 8.

20.

Magnesium sulfate potentiates effect of DigiFab on marinobufagenin-induced Na/K-ATPase inhibition.

Zazerskaya IE, Ishkaraeva VV, Frolova EV, Solodovnikova NG, Grigorova YN, David Adair C, Fedorova OV, Bagrov AY.

Am J Hypertens. 2013 Nov;26(11):1269-72. doi: 10.1093/ajh/hpt117. Epub 2013 Jul 22.

Supplemental Content

Loading ...
Support Center